Chimerix Announces Fourth Quarter and Full Year 2018 Financial Results
– Reports Positive Preliminary Top-line Data from Second Rabbitpox Study – – Type C Meeting Requested with FDA Regarding Virologic Endpoint – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., March 05, 2019 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), …